Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias D Becker

Showing results (11-20 of 47) with videos related to

Pageof 5
Sort By:
Retina (Philadelphia, Pa.)|January 11, 2008
Intravitreal bevacizumab (avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot studyFriederike Mackensen, Carsten Heinz, Matthias D Becker, et al.
International Journal of Retina and Vitreous|November 17, 2016
Aflibercept in branch retinal vein occlusion as second line therapy: clinical outcome 12 months after changing treatment from bevacizumab/ranibizumab-a pilot studyMagdalena A Wirth, Matthias D Becker, Nicole Graf, et al.
Drugs|March 1, 2005
Management of sight-threatening uveitis: new therapeutic optionsMatthias D Becker, Justine R Smith, Regina Max, et al.
American Journal of Ophthalmology|March 31, 2018
Pars Plana Vitrectomy for the Treatment of UveitisChristopher R Henry, Matthias D Becker, Yongsheng Yang, et al.
Clinical Ophthalmology (Auckland, N.Z.)|October 7, 2021
Assessment of Reinjection Numbers and Intervals for Diabetic Macular Edema Patients Who Received Dexamethasone Intravitreal Implants in Germany and SwitzerlandAlbert J Augustin, Matthias D Becker, Katja Hatz, et al.
Journal of Ophthalmology|March 21, 2017
Comparison of Progression Rate of Retinal Pigment Epithelium Loss in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab and AfliberceptJuliana Wons, Magdalena A Wirth, Nicole Graf, et al.
Ocular Immunology and Inflammation|September 15, 2005
Long-term follow-up of patients with birdshot retinochoroidopathy treated with systemic immunosuppressionMatthias D Becker, Michael S Wertheim, Justine R Smith, et al.
Ophthalmic Research|September 29, 2015
Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusionMaximilian Pfau, Heidi Fassnacht-Riederle, Matthias D Becker, et al.
Retina (Philadelphia, Pa.)|August 3, 2017
IMPACT OF LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ON PREEXISTING MICROSTRUCTURAL ALTERATIONS IN DIABETIC MACULAR EDEMAMagdalena A Wirth, Juliana Wons, Florentina J Freiberg, et al.
American Journal of Ophthalmology|August 23, 2008
QuantiFERON TB-Gold--a new test strengthening long-suspected tuberculous involvement in serpiginous-like choroiditisFriederike Mackensen, Matthias D Becker, Ute Wiehler, et al.
Pageof 5

Showing results (11-20 of 47) with videos related to

Sort By:
Pageof 5
Retina (Philadelphia, Pa.)|January 11, 2008
Intravitreal bevacizumab (avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot studyFriederike Mackensen, Carsten Heinz, Matthias D Becker, et al.
International Journal of Retina and Vitreous|November 17, 2016
Aflibercept in branch retinal vein occlusion as second line therapy: clinical outcome 12 months after changing treatment from bevacizumab/ranibizumab-a pilot studyMagdalena A Wirth, Matthias D Becker, Nicole Graf, et al.
Drugs|March 1, 2005
Management of sight-threatening uveitis: new therapeutic optionsMatthias D Becker, Justine R Smith, Regina Max, et al.
American Journal of Ophthalmology|March 31, 2018
Pars Plana Vitrectomy for the Treatment of UveitisChristopher R Henry, Matthias D Becker, Yongsheng Yang, et al.
Clinical Ophthalmology (Auckland, N.Z.)|October 7, 2021
Assessment of Reinjection Numbers and Intervals for Diabetic Macular Edema Patients Who Received Dexamethasone Intravitreal Implants in Germany and SwitzerlandAlbert J Augustin, Matthias D Becker, Katja Hatz, et al.
Journal of Ophthalmology|March 21, 2017
Comparison of Progression Rate of Retinal Pigment Epithelium Loss in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab and AfliberceptJuliana Wons, Magdalena A Wirth, Nicole Graf, et al.
Ocular Immunology and Inflammation|September 15, 2005
Long-term follow-up of patients with birdshot retinochoroidopathy treated with systemic immunosuppressionMatthias D Becker, Michael S Wertheim, Justine R Smith, et al.
Ophthalmic Research|September 29, 2015
Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusionMaximilian Pfau, Heidi Fassnacht-Riederle, Matthias D Becker, et al.
Retina (Philadelphia, Pa.)|August 3, 2017
IMPACT OF LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ON PREEXISTING MICROSTRUCTURAL ALTERATIONS IN DIABETIC MACULAR EDEMAMagdalena A Wirth, Juliana Wons, Florentina J Freiberg, et al.
American Journal of Ophthalmology|August 23, 2008
QuantiFERON TB-Gold--a new test strengthening long-suspected tuberculous involvement in serpiginous-like choroiditisFriederike Mackensen, Matthias D Becker, Ute Wiehler, et al.
Pageof 5